CHGB and pancreatic neuroendocrine tumor: Furthermore, although only a small percentage of patients with pancreatic neuroendocrine tumors exhibit elevated serum levels of pancreastatin and CHGB, ranging from 17 to 57%, their clinical significance remains uncertain.